头颈癌患者个体化择区淋巴结照射以减少并发症(iNode):一项Ⅰ期可行性试验方案
本研究为Ⅰ期可行性试验方案,计划纳入20例源于口咽、下咽或喉的cT2-4N0-1M0头颈鳞癌患者,在接受双侧择区颈部照射时,按细胞学、组织学和影像参数将常规淋巴结引流区内的个体淋巴结分为低、中、高危,分别给予20、23、35次照射,主要终点为在磁共振直线加速器上成功完成的分次百分比。
要点
- 计划纳入20例cT2-4N0-1M0口咽、下咽或喉头颈鳞癌患者,接受原发放疗及双侧择区颈部照射。
- 低危淋巴结照射20次、中危23次(分次剂量2 Gy,分别相当于40/46 Gy EQD2),高危淋巴结及原发肿瘤照射35次×2 Gy(相当于70 Gy EQD2)。
- 主要研究终点为在磁共振直线加速器上成功完成的分次百分比;磁共振直线加速器治疗时间较常规加速器延长(每分次30-45分钟 vs 15分钟)。
核心结论
- 作者预期个体化择区淋巴结照射可减少头颈鳞癌患者的毒性并改善生活质量,但因磁共振直线加速器治疗时间较长(每分次30-45分钟 vs 15分钟),需评估患者能否耐受这一新治疗模式。
研究设计与样本
- 本研究为Ⅰ期可行性试验方案,计划纳入20例经组织学证实的cT2-4N0-1M0头颈鳞癌患者,原发部位为口咽、下咽或喉,计划接受原发放疗及双侧择区颈部照射。
主要发现
- 常规淋巴结引流区内的个体淋巴结根据细胞学、组织学和影像参数分为低危、中危和高危。
- 低危和中危淋巴结分别照射20次和23次,分次剂量2 Gy(分别相当于40/46 Gy EQD2)。
- 高危淋巴结和原发肿瘤照射35次×2 Gy(相当于70 Gy EQD2)。
- 为减轻治疗负担,其中20次在磁共振直线加速器上实施,最后15次(原发肿瘤、中危和高危淋巴结的序贯加量)在常规直线加速器上实施。
- 主要研究终点为在磁共振直线加速器上成功完成的分次百分比。
关键数值与推荐
- 低危淋巴结:20次,分次剂量2 Gy,相当于40 Gy EQD2。
- 中危淋巴结:23次,分次剂量2 Gy,相当于46 Gy EQD2。
- 高危淋巴结及原发肿瘤:35次×2 Gy,相当于70 Gy EQD2。
- 放疗按DAHANCA方案,共35次、六周完成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 磁共振直线加速器治疗时间较长(每分次30-45分钟 vs 15分钟),需评估患者能否耐受这一新治疗模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The long-term complication rate in head-and-neck squamous cell carcinoma (HNSCC) patients caused by radiotherapy (RT) can be decreased by restricting elective neck irradiation (ENI) from large adjacent lymph node levels to only individual elective lymph nodes. The primary objective of this study is to treat the first HNSCC patients with individual elective lymph node irradiation by means of a Magnetic Resonance-linac (MR-linac) in order to assess the feasibility. METHODS AND ANALYSIS: In this phase I feasibility study, 20 patients will be included with histologically proven cT2-4N0-1M0 HNSCC originating from the oropharynx, hypopharynx or larynx, planned for treatment with primary radiotherapy and bilateral elective neck irradiation (ENI). Patients will be treated with 35 fractions in six weeks, according to the DAHANCA schedule. Individual lymph nodes inside the conventional lymph node levels will be categorized in low-risk, intermediate-risk and high-risk based on cytology, histology and imaging parameters. Low-risk and intermediate-risk lymph nodes will irradiated in 20 and 23 fractions respectively, with a fraction dose of 2 Gy (=40/46 Gy EQD2). The high-risk lymph nodes and the primary tumor will be irradiated in 35 fractions of 2 Gy (=70 Gy equivalent dose in 2 Gy fractions (EQD2)). To limit treatment burden, 20 fractions will be applied on the MR-linac. The last 15 fractions (sequential boost at the primary tumor, intermediate-risk and high-risk lymph nodes) will be applied on a conventional linear accelerator. The main study endpoint is the percentage of fractions that are successfully completed on the MR-linac. ETHICS AND DISSEMINATION: With individual elective lymph node irradiation we expect less toxicity and a better quality of life for HNSCC patients. However, as the treatment time on the MR-linac will be longer (30-45 vs 15 min per fraction) we need to examine if patients can endure this new treatment concept.
引用
- Reinders FCJ, de Ridder M, Doornaert PAH, et al. Individual elective lymph node irradiation for the reduction of complications in head and neck cancer patients (iNode): A phase-I feasibility trial protocol. Clin Transl Radiat Oncol. 2022. PMID: 36686561. doi:10.1016/j.ctro.2022.100574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。